My Blue Dots

AUSTIN, Texas–(BUSINESS WIRE)– #JPM2025–Gameto to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO & BERLIN & DURHAM, N.C.–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. 550 subjects were random

TORONTO–(BUSINESS WIRE)—- $ALGO #Cboe–Light AI Inc. is available for trading on the Cboe Canada exchange under the symbol ALGO.

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease. KAN-101 ind

SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipol

DENVER–(BUSINESS WIRE)–TriSalus announces leadership changes.

BRANFORD, Conn.–(BUSINESS WIRE)–Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics

SAN DIEGO & OXFORD, England–(BUSINESS WIRE)– #AploScope–ONI (Oxford Nanoimaging), a life science tools company focused on developing super-resolution microscopy, announced today the launch of the Aplo Scope, a single molecule super-resolution microscope that enables scientists to observe and measure molecular interactions within cells and tissues with unparalleled precision. The Aplo Scope addresses a critical challenge in single-molecule research—capturing the intricate details of biological systems in

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for Development and Production of Radiopharmaceutical Products